Precision Medicine

As RenovoRx preps its Q2 update, it's proving its mettle on two fronts: impressive sales of its RenovoCath device and a critical milestone in its pancreatic cancer trial.

The FNIH is launching a landmark study using AI and biomarkers to redefine depression, moving beyond guesswork toward precision care for millions.

An FDA panel's nod to controversial peptides seems to validate Hydreight's long-term strategy. But a closer look reveals a long road and a deep data gap.

Solid Q2 earnings are just the start. Photocure is moving beyond its core imaging tech with key acquisitions and AI partnerships, building a full-spectrum platform.

A new partnership between Longevity AI and Clalit Health leverages a massive national dataset to recalibrate risk models and stop chronic disease in its tracks.

BGLC aims to upend cancer monitoring in emerging markets with a low-cost liquid biopsy. But can a micro-cap execute on this billion-dollar vision?

Firefly's AI brain mapping joins Next Health's peptide therapies, spurred by a key FDA panel vote. Is this the future of cognitive care or a risky leap?

Lantern Pharma's EMA-cleared trial for LP-184 uses a dual-biomarker strategy, targeting a multi-billion dollar market where patient options are scarce.

A landmark FDA approval allows Walter Reed to 3D-print cranial implants on-site, a strategic shift in military medicine powered by 3D Systems' expertise.

A new biotech, CORE Biomedicine, armed with Eisai's preclinical assets and a $21M Series A, aims to upend oncology by targeting cancer's 'lineage' identity.

With $21M in funding and a novel 'lineage-based' approach, CORE Biomedicine is moving beyond genomics to target the root cause of cancer's identity.

With two blockbuster cancer drugs driving revenue, Syndax's upcoming Q2 report is a critical test of its path to profitability and ambitious pipeline.

Lowcountry Male & Aqua Vitae's 10th clinic in 10 years isn't just growth; it's a case study in the shift from reactive medicine to personalized wellness.

Aman Clinics' partnership with US-based Cenegenics brings elite, data-driven longevity medicine to Doha, signaling a major shift in the region's healthcare.

Thermo Fisher's latest innovations tackle medicine's toughest challenges, from cancer to preeclampsia, using automation and rapid data to redefine diagnostics.

FDA clears a pivotal study for Medicus Pharma's SkinJect, a microneedle patch offering new hope for Gorlin Syndrome and a new playbook in biotech strategy.

A novel partnership aims to create the first drug for ReNU syndrome, a condition found in 2024, potentially redefining rare disease drug development.

A Yale symposium reveals a new economic force: patient advocacy groups are directing capital and innovation in the fight against complex diseases.

Waters Corp. has launched a mass spectrometer promising a new era of diagnostic sensitivity. But can its operational robustness overcome the real-world hurdles?

A breakthrough trial for a rare genetic disorder unlocks $50M in funding. We explore the novel RNA science, the savvy investment, and why it's all happening in Australia.